Improving first-line antiretroviral therapy in resource-limited settings.
about
An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaquesHIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settingsPrevalence, clinical and virologic outcomes of hepatitis B virus co-infection in HIV-1 positive Kenyan women on antiretroviral therapyWhen to start antiretroviral therapy in resource-limited settings: a human rights analysis.Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration.Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175).The first decade of antiretroviral therapy in Africa.Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South AfricaImproved survival in HIV treatment programmes in AsiaDevelopment, Validation, and Field-Testing of an Instrument for Clinical Assessment of HIV-Associated Neuropathy and Neuropathic Pain in Resource-Restricted and Large Population Study SettingsPreferred antiretroviral drugs for the next decade of scale up.Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges.Accuracy of immunological criteria for identifying virological failure in children on antiretroviral therapy - the IeDEA Southern Africa CollaborationClinical Outcomes of Tenofovir Versus Zidovudine-based Regimens Among People Living with HIV/AIDS: a Two Years Retrospective Cohort Study.Forgotten, not neglected: viral hepatitis in resource-limited settings, recall for action.Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
P2860
Q27438093-5D7AC40C-FAA5-4A36-A610-BA8E6F3DAFFCQ28088839-1A2588AB-E6F9-4CDE-804F-011F85144DB3Q28488149-87949DEE-3FEB-43B5-9959-DF3E26FB10CDQ33548096-566E229C-9F34-4479-84BB-66F7AFA120C8Q35014160-D672BC81-6F91-4349-BF87-6F1367B4479CQ35170350-C539D7DE-997F-4129-BA9B-91B163835F25Q35337985-9868D94E-6599-43DE-8AF6-74C87755E9E5Q35856520-959AAA31-88EF-4BB5-AE04-FF0814362E7AQ35951760-105DE06D-6D0E-4319-BC9E-A74ABD90A41DQ36169291-071778C8-01BE-4E23-A703-34DEBA2A1370Q36386810-15C9DC17-66B7-4CFA-A31A-5C85B8EC31D1Q36821936-942965B3-8DCC-44D5-91E3-48186B1794F6Q37199247-2E8C7734-0178-4258-B80B-10C1303CA62EQ37635145-C0E3BABE-65B1-4C35-8EDE-FD78D33EE96CQ42249024-2EDC97BB-0387-4E1C-95D1-07512E49D4D9Q43414255-BF3F8670-7DEA-4671-94BB-9044B3E5278F
P2860
Improving first-line antiretroviral therapy in resource-limited settings.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Improving first-line antiretroviral therapy in resource-limited settings.
@en
Improving first-line antiretroviral therapy in resource-limited settings.
@nl
type
label
Improving first-line antiretroviral therapy in resource-limited settings.
@en
Improving first-line antiretroviral therapy in resource-limited settings.
@nl
prefLabel
Improving first-line antiretroviral therapy in resource-limited settings.
@en
Improving first-line antiretroviral therapy in resource-limited settings.
@nl
P1476
Improving first-line antiretroviral therapy in resource-limited settings.
@en
P2093
Nathan Ford
P356
10.1097/COH.0B013E3283339B41
P577
2010-01-01T00:00:00Z